Vital Therapies (VTL) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Vital Therapies Announces Second Quarter Financial Results
August 2, 2016 4:01 PM EDTSAN DIEGO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the second quarter ended June 30, 2016.
Key Recent Developments
Eight subjects have been enrolled at sites in the United States and Europe in VTL-308, the Companys phase 3 randomized, controlled, open-label trial, designed to evaluate the ELAD System in subjects with severe... More